was read the article
array:21 [ "pii" => "X2013251409033669" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:604-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4425 "formatos" => array:3 [ "EPUB" => 274 "HTML" => 3619 "PDF" => 532 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699509033661" "issn" => "02116995" "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2009;29:604-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10525 "formatos" => array:3 [ "EPUB" => 260 "HTML" => 9611 "PDF" => 654 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "604" "paginaFinal" => "607" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "451527_figura1.jpg" "Alto" => 275 "Ancho" => 600 "Tamanyo" => 78564 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Martínez-Sánchez, José María Morales, A. Andrés, E. Olavarria, D. Marín" "autores" => array:8 [ 0 => array:2 [ "Iniciales" => "M." "apellidos" => "Castillo-Rama" ] 1 => array:2 [ "Iniciales" => "E." "apellidos" => "Paz-Artal" ] 2 => array:2 [ "Iniciales" => "C." "apellidos" => "Grande" ] 3 => array:2 [ "Iniciales" => "P." "apellidos" => "Martínez-Sánchez" ] 4 => array:2 [ "nombre" => "José María" "apellidos" => "Morales" ] 5 => array:2 [ "Iniciales" => "A." "apellidos" => "Andrés" ] 6 => array:2 [ "Iniciales" => "E." "apellidos" => "Olavarria" ] 7 => array:2 [ "Iniciales" => "D." "apellidos" => "Marín" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251409033669" "doi" => "10.3265/Nefrologia.2009.29.6.5346.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033661?idApp=UINPBA000064" "url" => "/02116995/0000002900000006/v0_201502091341/X0211699509033661/v0_201502091342/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251409033642" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:608-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3238 "formatos" => array:3 [ "EPUB" => 253 "HTML" => 2511 "PDF" => 474 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Continuous extrarenal treatment without anticoagulation therapy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "608" "paginaFinal" => "609" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Depuración extrarrenal continua sin anticoagulación" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luciano Santana Cabrera, M. Sánchez Palacios, A. Ramírez Rodríguez, A. Villanueva Ortiz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Luciano" "apellidos" => "Santana Cabrera" ] 1 => array:2 [ "Iniciales" => "M." "apellidos" => "Sánchez Palacios" ] 2 => array:2 [ "Iniciales" => "A." "apellidos" => "Ramírez Rodríguez" ] 3 => array:2 [ "Iniciales" => "A." "apellidos" => "Villanueva Ortiz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509033645" "doi" => "10.3265/Nefrologia.2009.29.6.5611.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033645?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033642?idApp=UINPBA000064" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033642/v0_201502091612/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251409033489" "issn" => "20132514" "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2009;29:594-603" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6404 "formatos" => array:3 [ "EPUB" => 247 "HTML" => 5485 "PDF" => 672 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Convection versus diffusion: Is it time to make the change?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "594" "paginaFinal" => "603" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Convección versus difusión: ¿ha llegado el momento del cambio?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "44418078_t1_p596.jpg" "Alto" => 367 "Ancho" => 826 "Tamanyo" => 54252 ] ] "descripcion" => array:1 [ "en" => "Comparative studies between convective techniques and haemodialysis" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Luis Teruel Briones" "autores" => array:1 [ 0 => array:2 [ "nombre" => "José Luis" "apellidos" => "Teruel Briones" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699509033481" "doi" => "10.3265/Nefrologia.2009.29.6.5672.en.full" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699509033481?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033489?idApp=UINPBA000064" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033489/v0_201502091612/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "604" "paginaFinal" => "607" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "M. Castillo-Rama, E. Paz-Artal, C. Grande, P. Martínez-Sánchez, José María Morales, A. Andrés, E. Olavarria, D. Marín" "autores" => array:8 [ 0 => array:3 [ "Iniciales" => "M." "apellidos" => "Castillo-Rama" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "Iniciales" => "E." "apellidos" => "Paz-Artal" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "Iniciales" => "C." "apellidos" => "Grande" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 3 => array:3 [ "Iniciales" => "P." "apellidos" => "Martínez-Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 4 => array:4 [ "nombre" => "José María" "apellidos" => "Morales" "email" => array:1 [ 0 => "josemariamoralesc@yahoo.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 5 => array:3 [ "Iniciales" => "A." "apellidos" => "Andrés" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 6 => array:3 [ "Iniciales" => "E." "apellidos" => "Olavarria" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 7 => array:3 [ "Iniciales" => "D." "apellidos" => "Marín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Inmunología, Hospital 12 de Octubre, Madrid, Madrid, España, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Hematología, Hospital 12 de Octubre, Madrid, Madrid, España, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Servicio de Nefrología/Trasplante Renal, Hospital 12 de Octubre, Madrid, Madrid, España, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 3 => array:3 [ "entidad" => "Servicio de Hematología y Área de Terapia Celular, Hammersmith Hospital, Imperial College, Londres, Inglaterra, Gran Bretaña, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renal y hepatitis" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_f1_p605.jpg" "Alto" => 372 "Ancho" => 825 "Tamanyo" => 29019 ] ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Chronic myeloid leukaemia (CML) is a myeloproliferative disease characterised by clonal expansion of myeloid cells.<span class="elsevierStyleSup">1</span> The pathognomonic cytogenetic anomaly in CML is the Philadelphia chromosome,<span class="elsevierStyleSup">2</span> which is produced by reciprocal translocation of the two long arms of chromosomes 9 and 22.<span class="elsevierStyleSup">3</span> This translocation generates the BC-ABL fusion protein, which is responsible for the oncogenic effects in CML.</p><p class="elsevierStylePara">On only two occasions does the literature describe the use of Imatinib (Gleevec, Novartis), a BCR-ABL tyrosine kinase inhibitor for CML treatment, in a kidney transplant patient;<span class="elsevierStyleSup">4,5 </span>there are no described cases in a patient with a second transplant with hepatitis C and high cardiovascular and immunological risk.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CASE REPORT</span></p><p class="elsevierStylePara">Male patient 55 years of age with CML that reached the chronic stage following his second kidney transplant. The patient started haemodialysis for mesangiocapillary glomerulonephritis in 1976 when he was 24, and received a kidney transplant from a live donor in 1983. His immunosupressive treatment was azathioprine and steroids. In 1989, six years after the first transplant, he suffered an acute myocardial infarction. Two years later, he began haemodialysis treatment once again due to chronic rejection of the allograft.</p><p class="elsevierStylePara">In 1994, when the patient was 42, he received a second kidney transplant from a 44 year old female donor. The donor and the recipient share three HLA alleles (HLA A3, B8 and DR3). The panel reactive antibody (PRA) score was 29%, probably due to various blood transfusions during the course of the first transplant, and to the transplanted organ itself. Immunosuppressants initially administered following the second transplant consisted of steroids (0.5mg/kg/day), azathioprine (2mg/kg/day) and cyclosporine A (CyA) (10mg/day).</p><p class="elsevierStylePara">Following the transplant, the patient developed postischaemic acute tubular necrosis, which required two subsequent surgical procedures one month after the transplant to correct a urinary fistula. At the time of the surgical procedure, a kidney biopsy was performed which revealed acute stage 1 rejection; steroids were administered as rescue treatment (1g in four doses). Two years later, the azathioprine was substituted with mycophenolate (tables 1 and 2) because of decreased renal function with CyA.</p><p class="elsevierStylePara">The patient¿s progress was satisfactory until June 2000, when a routine analysis revealed significant leukocytosis (34.5 x 109/l) and thrombocytosis (487 x 109/l) (figure 1). The patient experienced bilateral hip pain, but had no other symptoms. The examination was normal with no signs of spleen or liver enlargement.</p><p class="elsevierStylePara">An MRI scan of the hip showed diffused bone marrow involvement in almost all bones. The bone marrow aspiration and biopsy confirmed granulocytic and megakaryocytic hyperplasia compatible with CML. No fibrosis was observed in the bone marrow and the patient was low-risk according to the Sokal index.</p><p class="elsevierStylePara">The presence of the Philadelphia chromosome (46XY t[9;22][q34;q11]) was detected by analysing the bone marrow karyotype. Subsequent cytogenic molecular analyses with fluorescent in situ hybridation (FISH) revealed the presence of the BCR-ABL fusion gene in 90% of the nuclei. The RT-PCR confirmed the typical rearrangement of p210 BCR-ABL with the fusion transcript b2a2. During two months, the patient was treated with hydroxyurea, with no results. In September of this year, the patient was placed in a clinical trial of Novartis STI571-0113 and received 400mg of Imatinib daily; he showed a good tolerance of the drug with no adverse effects. The patient went into complete, sustained haematological remission, complete cytogenetic remission, and molecular remission at two, six and nine months respectively, and this continues to be the case today (figure 2). Fourteen years after his second transplant, the patient maintains an acceptable level of renal function (stage III chronic renal disease) and has not experienced acute rejection, decreased hepatic function or new cardiovascular events (table 1).</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">This case shows that Imatinib is a safe, effective drug for the treatment of CML in kidney transplant patients. Our patient responded rapidly to the treatment: peripheral blood and bone marrow became normal in the first two months, and cytogenetic and molecular remission occurred during the first year of treatment. These results are in line with IRIS1 study, which showed a complete cytogenetic response in 89% of patients with a low Sokal index, and a survival rate of 83%. Lastly, that study and our patient¿s case both show that an early cytogenetic and molecular response is associated with better long-term evolution and a lower risk of progression to the accelerated phase or blast crisis.<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">The use of Imatinib in this patient may also have had a beneficial immunosuppressant effect for the transplanted kidney, as suggested by recent in-vitro and animal studies showing that this drug may have immunomodulating effects. Appel et al. showed that Imatinib can inhibit the differentiation of CD34+ stem cells into dendritic cells (DC). Furthermore, T-cell activation may be inhibited, since DC cells¿ secretion of cytokines and chemokines decreases.<span class="elsevierStyleSup">7</span> Imatinib also inhibits the development of monocytes and macrophages in bone marrow progenitor cells.<span class="elsevierStyleSup">8 </span>Lastly, Dietz et al. showed that Imatinib can inhibit T-cell proliferation by arresting the proliferation of lymphocytes in G<span class="elsevierStyleInf">0</span> phase.</p><p class="elsevierStylePara">Some studies suggest that imatinib in the presence of cyclosporine can cause renal failure due to acute tubular necrosis.<span class="elsevierStyleSup">10,11</span> Despite receiving both drugs, our patient¿s renal function remained stable from the moment when treatment with Imatinib was started. Creatinine levels oscillated between 1.75 and 2.4mg/dl with low levels of proteinuria (the maximum proteinuria level was 0.56g/dl), (table 1).</p><p class="elsevierStylePara">Serious hepatic side effects have also been described, including fulminant liver failure associated with imatinib treatment.<span class="elsevierStyleSup">12-15</span> Our patient, who was positive for HCV, experienced no changes in liver function during treatment. Liver function remained within the normal range at all times, despite having detectable HCV RNA in blood plasma, which tends to be the case for most HCV patients following a transplant.<span class="elsevierStyleSup">16</span> (Table 3).</p><p class="elsevierStylePara">Imatinib, according to the manufacturer, may have adverse effects in cardiac patients due to the risk of heart failure. Our patient, who suffered a myocardial infarction at the age of 37, has experienced no adverse effects and his cardiac stress test this year was normal.</p><p class="elsevierStylePara">We conclude that imatinib is a safe and effective treatment for kidney transplant patients with CML. Furthermore, in vitro and animal studies suggest that the drug may have immunomodulating effects that could be beneficial for a transplant. <br></br></p><p class="elsevierStylePara"><a href="grande/45118078_f1_p605.jpg" class="elsevierStyleCrossRefs"><img src="45118078_f1_p605.jpg"></img></a></p><p class="elsevierStylePara">Figure 1. </p><p class="elsevierStylePara"><a href="grande/45118078_t1_p606.jpg" class="elsevierStyleCrossRefs"><img src="45118078_t1_p606.jpg" alt="Patient's renal function over the last 13 years"></img></a></p><p class="elsevierStylePara">Table 1. Patient's renal function over the last 13 years</p><p class="elsevierStylePara"><a href="grande/45118078_t2_606.jpg" class="elsevierStyleCrossRefs"><img src="45118078_t2_606.jpg" alt="Creatinine, cyclosporin (CyA) and mycophenolate (MMF) levels during treatment with imatinib"></img></a></p><p class="elsevierStylePara">Table 2. Creatinine, cyclosporin (CyA) and mycophenolate (MMF) levels during treatment with imatinib</p><p class="elsevierStylePara"><a href="grande/45118078_t3_p606.jpg" class="elsevierStyleCrossRefs"><img src="45118078_t3_p606.jpg" alt="Liver function and hep C status from one month after starting treatment"></img></a></p><p class="elsevierStylePara">Table 3. Liver function and hep C status from one month after starting treatment</p><p class="elsevierStylePara"><a href="grande/45118078_f2_p607.jpg" class="elsevierStyleCrossRefs"><img src="45118078_f2_p607.jpg"></img></a></p><p class="elsevierStylePara">Figure 2. </p>" "pdfFichero" => "P-E-S-A451-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438219" "palabras" => array:1 [ 0 => "Chronic myeloid leukemia" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438221" "palabras" => array:1 [ 0 => "renal transplant" ] ] ] "es" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438220" "palabras" => array:1 [ 0 => "trasplante renal" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438222" "palabras" => array:1 [ 0 => "Leucemia mieloide crónica" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:1 [ "resumen" => "Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors." ] "es" => array:1 [ "resumen" => "<p class="elsevierStylePara">La leucemia mieloide crónica (LMC) es una enfermedad mieloproliferativa caracterizada por la expansión clonal de células mieloides que expresan la proteína de fusión BCR-ABL, responsable de los efectos oncogénicos de la LMC. La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tirosín-kinasa, imatinib. Aunque este fármaco ha demostrado mejorar la supervivencia en pacientes con LMC, su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura. Presentamos un caso de remisión molecular de LMC en un varón de 55 años con un segundo trasplante renal, hepatitis C y con riesgos cardiovasculares e inmunológicos asociados.</p>" ] ] "multimedia" => array:5 [ 0 => array:7 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_f1_p605.jpg" "Alto" => 372 "Ancho" => 825 "Tamanyo" => 29019 ] ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_t1_p606.jpg" "Alto" => 134 "Ancho" => 826 "Tamanyo" => 23808 ] ] "descripcion" => array:1 [ "en" => "Patient's renal function over the last 13 years" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_t2_606.jpg" "Alto" => 156 "Ancho" => 826 "Tamanyo" => 29652 ] ] "descripcion" => array:1 [ "en" => "Creatinine, cyclosporin (CyA) and mycophenolate (MMF) levels during treatment with imatinib" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_t3_p606.jpg" "Alto" => 233 "Ancho" => 827 "Tamanyo" => 40890 ] ] "descripcion" => array:1 [ "en" => "Liver function and hep C status from one month after starting treatment" ] ] 4 => array:7 [ "identificador" => "fig5" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "45118078_f2_p607.jpg" "Alto" => 368 "Ancho" => 824 "Tamanyo" => 25738 ] ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:16 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11287972" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1525861013000388" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961;27:1013-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14480645" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4126434" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, et al. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation Clin Nephrol 2005;64(4):324-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16240908" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007;22(6):1791-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17308316" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Druker BJ, Guilhot F, O¿Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17151364" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23(8):1082-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16140870" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. Immunol Cell Biol 2005;83(1):48-56. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661041" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104(4):1094-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15100154" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002;17(4):685-7." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003;44(7):1239-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12916879" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chen L, Wang JM, Xu XP Gao L, Fei XH, Lou JW, et al. The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Abstract) 2003;11(6):600-3." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1525861011002568" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-11." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81(3):189-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16493605" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1525861013003022" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12(1):49-53. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17364993" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Morales JM, Campistol JM.Transplantation in the Patient with Hepatitis C. J Am Soc Nephrol 2000;11:1343-53. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10864593" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/main.assets" "Apartado" => array:4 [ "identificador" => "35422" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case Reports" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002900000006/v0_201502091611/X2013251409033669/v0_201502091612/en/P-E-S-A451-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251409033669?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 6 | 6 | 12 |
2024 October | 78 | 47 | 125 |
2024 September | 60 | 44 | 104 |
2024 August | 66 | 88 | 154 |
2024 July | 47 | 45 | 92 |
2024 June | 75 | 52 | 127 |
2024 May | 71 | 46 | 117 |
2024 April | 71 | 44 | 115 |
2024 March | 55 | 36 | 91 |
2024 February | 53 | 49 | 102 |
2024 January | 44 | 36 | 80 |
2023 December | 51 | 28 | 79 |
2023 November | 58 | 37 | 95 |
2023 October | 69 | 58 | 127 |
2023 September | 85 | 33 | 118 |
2023 August | 54 | 30 | 84 |
2023 July | 45 | 31 | 76 |
2023 June | 43 | 20 | 63 |
2023 May | 48 | 33 | 81 |
2023 April | 36 | 16 | 52 |
2023 March | 45 | 24 | 69 |
2023 February | 35 | 31 | 66 |
2023 January | 35 | 25 | 60 |
2022 December | 42 | 24 | 66 |
2022 November | 49 | 33 | 82 |
2022 October | 43 | 53 | 96 |
2022 September | 31 | 30 | 61 |
2022 August | 60 | 44 | 104 |
2022 July | 31 | 46 | 77 |
2022 June | 42 | 26 | 68 |
2022 May | 47 | 29 | 76 |
2022 April | 43 | 42 | 85 |
2022 March | 30 | 36 | 66 |
2022 February | 42 | 40 | 82 |
2022 January | 41 | 22 | 63 |
2021 December | 34 | 38 | 72 |
2021 November | 37 | 39 | 76 |
2021 October | 39 | 45 | 84 |
2021 September | 28 | 28 | 56 |
2021 August | 32 | 32 | 64 |
2021 July | 38 | 33 | 71 |
2021 June | 31 | 18 | 49 |
2021 May | 30 | 25 | 55 |
2021 April | 76 | 31 | 107 |
2021 March | 37 | 12 | 49 |
2021 February | 36 | 16 | 52 |
2021 January | 61 | 16 | 77 |
2020 December | 61 | 12 | 73 |
2020 November | 42 | 7 | 49 |
2020 October | 29 | 11 | 40 |
2020 September | 27 | 5 | 32 |
2020 August | 38 | 7 | 45 |
2020 July | 30 | 10 | 40 |
2020 June | 27 | 12 | 39 |
2020 May | 43 | 8 | 51 |
2020 April | 34 | 16 | 50 |
2020 March | 38 | 7 | 45 |
2020 February | 35 | 18 | 53 |
2020 January | 39 | 15 | 54 |
2019 December | 46 | 21 | 67 |
2019 November | 71 | 22 | 93 |
2019 October | 31 | 13 | 44 |
2019 September | 28 | 18 | 46 |
2019 August | 26 | 17 | 43 |
2019 July | 47 | 22 | 69 |
2019 June | 34 | 12 | 46 |
2019 May | 51 | 13 | 64 |
2019 April | 69 | 30 | 99 |
2019 March | 25 | 21 | 46 |
2019 February | 19 | 16 | 35 |
2019 January | 26 | 12 | 38 |
2018 December | 68 | 27 | 95 |
2018 November | 49 | 15 | 64 |
2018 October | 55 | 8 | 63 |
2018 September | 59 | 8 | 67 |
2018 August | 40 | 16 | 56 |
2018 July | 49 | 12 | 61 |
2018 June | 41 | 12 | 53 |
2018 May | 56 | 14 | 70 |
2018 April | 31 | 4 | 35 |
2018 March | 55 | 6 | 61 |
2018 February | 43 | 6 | 49 |
2018 January | 39 | 7 | 46 |
2017 December | 54 | 10 | 64 |
2017 November | 41 | 5 | 46 |
2017 October | 36 | 8 | 44 |
2017 September | 40 | 8 | 48 |
2017 August | 58 | 36 | 94 |
2017 July | 52 | 15 | 67 |
2017 June | 47 | 13 | 60 |
2017 May | 63 | 6 | 69 |
2017 April | 49 | 6 | 55 |
2017 March | 44 | 4 | 48 |
2017 February | 29 | 8 | 37 |
2017 January | 26 | 1 | 27 |
2016 December | 64 | 4 | 68 |
2016 November | 85 | 5 | 90 |
2016 October | 108 | 10 | 118 |
2016 September | 156 | 6 | 162 |
2016 August | 195 | 4 | 199 |
2016 July | 172 | 5 | 177 |
2016 June | 120 | 0 | 120 |
2016 May | 140 | 0 | 140 |
2016 April | 84 | 0 | 84 |
2016 March | 77 | 0 | 77 |
2016 February | 85 | 0 | 85 |
2016 January | 74 | 0 | 74 |
2015 December | 120 | 0 | 120 |
2015 November | 89 | 0 | 89 |
2015 October | 96 | 0 | 96 |
2015 September | 86 | 0 | 86 |
2015 August | 60 | 0 | 60 |
2015 July | 63 | 0 | 63 |
2015 June | 38 | 0 | 38 |
2015 May | 46 | 0 | 46 |
2015 April | 6 | 0 | 6 |